EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tri-Phenyl-Phosphonium-Based Nano Vesicles: A New In Vitro Nanomolar-Active Weapon to Eradicate PLX-Resistant Melanoma Cells

Silvana Alfei iD, Carola Torazza iD, Francesca Bacchetti iD, Maria Grazia Signorello, Mario Passalacqua iD, Cinzia Domenicotti iD, Barbara Marengo iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26073227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Silvana Alfei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy. Hauptthemen laut MEDLINE: Melanoma, Drug Resistance, Neoplasm, Organophosphorus Compounds, Vemurafenib. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous metastatic melanoma (CMM) is the most aggressive form of skin cancer, with characteristics including a poor prognosis, chemotherapy-induced secondary tumorigenesis, and the emergence of drug resistance. Our recent study demonstrated that triphenyl phosphonium (TPP)-based nanovesicles (BPPB), which have amphiphilic properties, exert potent ROS-dependent anticancer effect against PLX4032 (PLX)-sensitive MeOV BRAFV600E and MeTRAV BRAFV600D mutant cell lines, evidencing more marked efficacy on MeOV cells. Here, taking advantage of this in vitro model, the antitumoral effect of BPPB was tested on PLX-resistant (PLX-R) MeOV BRAFV600E and MeTRAV BRAFV600D mutant cell lines to find a new potential strategy to fight melanoma therapy resistance. Specifically, we investigated both its effects on cell viability in dose- and time-dependent experiments and those on ROS generation. Our results show that BPPB exerted strong antiproliferative effects, regardless of their acquired resistance of cells to PLX, that correlated with ROS overproduction for 24 h treatments only. Moreover, in terms of cell viability, PLX-R MeTRAV cells demonstrated a remarkably higher tolerance to 24 h BPPB treatment than PLX-R MeOV. On the contrary, BPPB exposure for longer periods induced similar responses in both cell lines (IC50 = 87.8–106.5 nM on MeOV and 81.0–140.6 nM on MeTRAV). Notably, BPPB cytotoxicity on non-tumorigenic human keratinocytes (HaCaT) was low, thus establishing that BPPB is appreciably selective for CMM cells, allowing for selectivity index values (SIs) up to 11.58. Furthermore, the BPPB concentration causing 50% hemolysis (HC50) was found to be 16–173 and 4–192-fold higher than the IC50 calculated for PLX-R MeOV and MeTRAV cells, respectively. Correlation studies established that BPPB exerts cytotoxic effects on PLX-R MeOV and MeTRAV cells by a time-dependent mechanism, while a concentration-dependent mechanism was observed only at 24 h of exposure. Finally, a ROS-dependent mechanism can be assumed only in PLX-R MeTRAV cells in 72 h treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaDrug Resistance, NeoplasmOrganophosphorus CompoundsVemurafenibAntineoplastic AgentsSkin NeoplasmsNanoparticlesHumansCell Line, TumorReactive Oxygen SpeciesCell SurvivalCell ProliferationProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

cell viability (%) studiescutaneous metastatic melanoma (CMM)low cytotoxicity on HaCaT cellslow hemolytic effectsnanosized bola-amphiphiles vesiclestriphenyl phosphonium (TPP) groups

Substanzen

Reactive Oxygen SpeciesOrganophosphorus CompoundsVemurafenibAntineoplastic AgentsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.
  • Biochemistry Laboratory, Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy.
  • Biochemistry Section, Department of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.
  • Centro 3R, Department of Information Engineering, University of Pisa, Largo Lucio Lazzarino 1, 56122 Pisa, Italy.
  • IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
  • Department of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.

ORCID-Profile: Silvana Alfei, Carola Torazza, Francesca Bacchetti, Mario Passalacqua, Cinzia Domenicotti, Barbara Marengo

Zitieren

APA

Alfei, S., Torazza, C., Bacchetti, F., Signorello, M. G., Passalacqua, M., Domenicotti, C., & Marengo, B. (2025). Tri-Phenyl-Phosphonium-Based Nano Vesicles: A New In Vitro Nanomolar-Active Weapon to Eradicate PLX-Resistant Melanoma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073227

Vancouver

Alfei S, Torazza C, Bacchetti F, Signorello MG, Passalacqua M, Domenicotti C, et al. Tri-Phenyl-Phosphonium-Based Nano Vesicles: A New In Vitro Nanomolar-Active Weapon to Eradicate PLX-Resistant Melanoma Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073227

BibTeX
@article{Alfei2025,
  author = {Alfei, Silvana and Torazza, Carola and Bacchetti, Francesca and Signorello, Maria Grazia and Passalacqua, Mario and Domenicotti, Cinzia and Marengo, Barbara},
  title = {Tri-Phenyl-Phosphonium-Based Nano Vesicles: A New In Vitro Nanomolar-Active Weapon to Eradicate PLX-Resistant Melanoma Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26073227}
}
Kostenlos starten →